(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 October 2023 (19.10.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/200427 A1

(51) International Patent Classification:
A61K 31/4745 (2006.01) *A61P 35/00* (2006.01)
A61K 45/06 (2006.01)

(21) International Application Number:
PCT/US2022/024312

(22) International Filing Date:
11 April 2022 (11.04.2022)

(25) Filing Language: English

(26) Publication Language: English

(72) Inventor; and
(71) Applicant: **ZHONG, Wei** [CN/US]; 957 Ferndale Dr, Corona, California 92881 (US).

(74) Agent: **YE, Jun**; Getech Law LLC, 203 N LaSalle, Suite 210, Chicago, Illinois US (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2023/200427 A1

(54) **Title:** SUBSTITUTED 1-(3,3-DIFLUOROPIPERIDIN-4-YL)-IMIDAZO[4,5-C] QUINOLIN-2-ONE DERIVATIVE CRYSTAL FORM, SALT CRYSTAL FORM, PREPARATION METHOD AND APPLICATION





(I)

FIG. 1

(57) **Abstract:** A substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one derivative (represented by the formula (I)) free base's crystal form and salt's crystal form, a preparation method and application are provided; specifically, the free base crystal form and fumarate salt crystal form of the 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one derivative represented by formula (I). The free base crystal form and salt crystal form provided by the present invention have good stability, which can be used in the treatment of cancers, cancers with CNS metastasis, meningeal metastasis, primary brain cancer or glioma, etc., especially combination with DNA double strand break inducing agents, and have good bioavailability and half-life, which are of great significance for further research on the efficacy of such solid drugs.